New York state and Virginia health centers on Friday asked a federal district judge to deny four insulin and diabetes drug manufacturers’ motion to dismiss the health centers’ antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
Upstate New York health center Mosaic Health sued Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca in late July 2021. Mosaic says the companies colluded to raise their prices by eliminating contract pharmacy 340B drug discounts, while protecting their market position from competition from one another, in violation of federal and state antitrust laws.
New York state and Virginia health centers on Friday asked a federal district judge to deny four insulin and diabetes drug manufacturers’ motion to dismiss the health centers’ antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
